论文部分内容阅读
目的：了解国产奥沙普秦肠溶胶囊在人体的药物动力学及相对生物利用度。方法：采用随机交叉试验设计，１０例男性健康者单剂量口服奥沙普秦肠溶胶囊与片剂 ６００ ｍｇ，以 ＨＰＬＣ法测定血药浓度。结果：胶囊与片剂各项动力学参数为：（１）ＡＵＱＯ ——（７５７２±ｓ ６９５） ｍｇ· Ｌ－１与（８２０１± ９４９）ｍｇ．Ｌ－１．ｈ－１；（２）Ｔ １／２－（５９±７） ｈ与（５３±４ ） ｈ ，上述２参数经ｔ检验；差别无统计学意义（Ｐ＞０． ０５）；（３） Ｃｍａｘ－－（８３± １５）ｍｇ．Ｌ－１与（１２６± ２１）ｍｇ·Ｌ－１；（４） Ｔｍａｘ－（１５± ７） ｈ与（４± ３） ｈ，经方差分析，均 Ｐ＜ ０． ０５，符合肠溶制剂原有性质。胶囊的相对生物利用度为（９３± １３）％，经双向单侧 ｔ检验作统计学分析，（Ｐ＞０．０５）。结论：胶囊与片剂两者之间具有生物等效性。
Objective: To understand the pharmacokinetics and relative bioavailability of domestic oxaprozen enteric-coated capsules in human. Methods: A randomized crossover trial was designed. One hundred doses of oxaliputan enteric-coated capsules and tablets were administered to 10 healthy male volunteers. Plasma concentrations were determined by HPLC. Results: The kinetic parameters of capsules and tablets were as follows: (1) AUQO - (7572 ± s 695) mg · L -1 and (8201 ± 949) mg respectively. L-1. h-1; (2) T 1 / 2- (59 ± 7) h and (53 ± 4) h, the two parameters were tested by t test; the difference was not statistically significant (P> 0.05) - (83 ± 15) mg. L-1 and (126 ± 21) mg · L-1; (4) Tmax- (15 ± 7) h and (4 ± 3) h, respectively. 05, in line with the original nature of enteric preparations. The relative bioavailability of capsules was (93 ± 13)%, and was analyzed by bi-directional unilateral t-test (P> 0.05). Conclusion: Bioequivalence between capsules and tablets.